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Human challenge studies (HCSs) involve deliberate infection of 
healthy volunteers with infectious agents and have been an important 
research approach for ~300 years.[1] Historically, this research strategy 
has been used for centuries, dating back formally to the development 
of the smallpox vaccine by Edward Jenner in the late 1700s.[2,3] 
However, the concept of variolation (inoculation of smallpox material 
into people who had not experienced smallpox) dates even further 
back to Asia and North Africa.[4] Stories of inoculation practices 
used in China, Turkey, Africa and India prior to the 17th century 
found their way to the Royal Society in London via letters based on 
conversations held with African slaves in Britain and Europe, and 
from British officials working with the Dutch East India Company 
in India.[3]
Although research in the 18th century has been described as a 
‘cottage industry’ where reliance on trial and error was all that could 
be done to establish efficacious interventions – a practice far removed 
from the randomised controlled clinical trials conducted by industry 
and academia today – Jenner had a keen scientific mind that he 
exercised well in his general practice in Britain. He had astute powers 
of observation, and while he did not have to submit his research 
ideas to regulatory bodies or research ethics committees, he and his 
peers conducted risk-benefit assessments on smallpox inoculations. 
The risk of dying from smallpox was 1 in 7 in the 1720s, while the 
risk of dying of deliberate inoculation was 1 in 100.[3] It was only in 
1802 that more formal trials were organised in Vienna and Boston, 
where children were vaccinated and then deliberately infected with 
smallpox. Interestingly, the Jenner Institute at Oxford University has 
pioneered work on a COVID-19 vaccine.
Over the past 50 years, HCSs have become a unique research 
tool in vaccine development, with typhoid and cholera[5,6] being 
good examples. Scientifically, HCSs could be of value because 
they potentially speed up vaccine development,[7] require fewer 
participants, so that there is less exposure to an experimental vaccine, 
and can be used to compare efficacy of multiple vaccine candidates 
and select the most promising vaccine for larger studies. [1] With 
COVID-19 specifically, HCSs may also be used to validate tests 
for immunity to SARS-CoV-2, to identify correlates of immune 
protection, and to investigate risks of transmission by infected 
individuals.[8]
For many fundamental reasons, HCSs are ethically and legally 
challenging. Deliberately infecting healthy adults with a virus 
may appear to be antithetical to ethical principles, especially the 
requirement to first do no harm. However, many argue that under 
certain conditions, such as pandemics, this may be acceptable. 
Nevertheless, careful study design is important to minimise harm. 
This design advantage can be achieved by recruiting young adults to 
whom COVID-19 poses least risk. It is known that in the UK, the risk 
of death from COVID-9 was <0.01% in those aged 18 - 39 years,[9] 
while this age group represented only 5% of hospitalisations.[10] In 
Africa, it would be important to establish which adults are at the 
lowest possible risk if they do contract COVID-19. In addition, 
specialised facilities and close monitoring would be necessary, as 
well as access to early supportive care including intensive care unit 
(ICU) beds, high-flow nasal oxygen and mechanical ventilation. 
In the context of COVID-19, the risks are especially high as there 
is currently no specific treatment and severe disease or death can 
occur in young adults. In Western Cape Province, South Africa (SA), 
0.04% of adults aged 20 - 39 years with confirmed COVID-19 died 
during the first wave of infection.[11] In a study of 1 376 patients 
treated at district hospitals in the Western Cape from March to June 
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2020, the mean age was 46.3 years and 58.5% were female.[12] New 
variants, such as the SARS-CoV-2 variant 501.V2, circulating during 
the second wave of infections since November 2020, may change the 
age distribution of cases, and this is currently being investigated.[13] 
Media reports, however, indicated that many younger South Africans 
had contracted the infection during the second wave.[14] Strategies to 
mitigate risks from an ethical perspective would include supporting 
valid informed consent, providing compensation for harm and 
burdens, providing efficacious treatment for infected participants, 
ensuring a reasonable likelihood of social benefit (access to vaccines), 
and a reasonable likelihood of faster development of vaccines relative 
to a conventional trial approach (‘acceleration argument’).
The World Health Organization (WHO) published guidance on 
the ethics of HCSs in May 2020 and listed eight criteria that must be 
met before these studies may be conducted:[15] 
• Strong scientific justification must be provided.
• Risks and potential benefits must be assessed.
• Stakeholder engagement is essential.
• Co-ordination among researchers, funders, policymakers and 
regulators should occur.
• Site selection must ensure the highest clinical, scientific and ethical 
standards.
• Participant selection must minimise or limit risk, so young adults 
(18 - 30 years) or healthcare workers are preferable.
• Instead of regular research ethics committee (REC) review, a 
specialised independent committee comprising scientific and 
ethics experts, preferably at a national or international level, 
is advised. WHO collaboration with local or national RECs is 
advisable.
• Informed consent must be rigorous and include a test of 
understanding and ongoing discussions as new information 
emerges that may impact on the consent process.
In addition to these criteria, harm mitigation strategies include 
supportive care, including ICU access, long-term follow-up, and full 
compensation for any harms suffered. SA has a long history of clinical 
trials experience, but expertise in HCSs is limited. Clinical trial sites 
are established, but not at the standards required for HCSs. Limiting 
participation to young adults reduces risk but limits generalisability, 
as has emerged with the local AstraZeneca COVID-19 vaccine 
trials, where results could only be extrapolated to prevention of mild 
and moderate disease and not to prevention of severe disease. [16] 
While limiting HCSs to young people is not necessarily ideal, 
selecting healthcare workers could be problematic as they may be 
older and have comorbidities, so WHO criterion 6 for participant 
selection is not ideal. Likewise, criterion 3 requiring stakeholder 
engagement is important, but has not been optimally implemented 
during the current Johnson & Johnson vaccine rollout in the form 
of an implementation trial, causing confusion and conflict among 
healthcare personnel in the public and private healthcare sectors and 
inconsistent criteria being applied across trial sites during the phase 
1 rollout. The constraints to achieving the site selection criteria and 
specialised independent ethics committee review in many African 
countries were not considered.
Finally, in assessing the relevance of the WHO approach to HCSs 
in SA, it is interesting to note that the WHO working group that 
developed these criteria had only one representative from Africa, 
from a Wellcome Trust-funded site in Kenya. The WHO report is 
therefore limited given minimal representation on the working group 
from other regions in Africa.
Globally, bioethicists argue both for and against HCS.
Arguments for HCSs
Arthur Caplan[17] strongly advocates for HCSs based on the risk-
benefit ratio. In his view, the benefits outweigh the risks, especially in 
the context of a pandemic. If society accepts the risks to healthcare 
workers exposed to COVID-19, we should accept the risks to healthy 
adult volunteers who participate with fully informed consent.[17] 
However, this argument does not adequately account for healthcare 
workers who also have personal protective equipment to protect 
them while treating COVID-19 patients. In a similar vein, Nir Eyal[18] 
supports the risk-benefit argument, taking illness and death during a 
pandemic into account as well as risks related to other interventions 
in regular healthcare. The net risk is important to consider, i.e. the 
risk of participating in an HCS ‘minus the risk that the same person 
would face otherwise’ in the community. He also argues that HCSs 
have an advantage because when the rates of infection decrease, 
traditional phase 3 trials are likely to experience recruitment and 
enrolment challenges. Finally, Caplan and Eyal both defend the 
‘acceleration argument’, i.e. that vaccine efficacy results could be 
obtained faster in HCSs compared with traditional clinical trials, and 
in the context of a deadly pandemic, greater speed will ultimately 
translate into greater saving of human lives.
Arguments against HCSs
Ruth Macklin,[19] a prominent bioethicist based at the Albert Einstein 
College of Medicine, disagrees with Caplan, Eyal and the WHO. 
While she acknowledges the public health imperative to save the 
most lives at the lowest cost (placing fewest research participants at 
risk), she argues that if there is no effective treatment available for 
COVID-19, such research is unjustifiable. She also raises concerns 
around the validity of informed consent, particularly considering 
that participants may be subject to the prevention misconception, 
i.e. believe in advance of the results that the vaccine is effective.[19] 
Kahn et al.[20] question the validity of the acceleration argument, 
i.e. whether it is true that HCSs can deliver reliable vaccine testing 
results significantly faster than designs more closely aligned with the 
traditional vaccine pathway. While HCSs are often justified in the 
context of limited spread of a pathogen in the natural environment, 
widespread exposure to SARS-CoV-2 during the pandemic has 
facilitated the conduct of traditional clinical trials. In fact, there are 
currently several vaccine candidates that, after phase 3 studies, have 
obtained emergency use authorisations and are in the process of 
being distributed en masse in several countries. In addition, various 
regulatory and logistic challenges would slow down the initiation 
of HCSs. These include selection of the most appropriate strain 
of the virus to use, manufacture of the strain in a BSL-3-certified 
laboratory that is compliant with Good Manufacturing Practice 
standards, obtaining regulatory approval from the Food and Drug 
Administration, and conducting dose-escalation studies.[21] Anna 
Durbin[22] estimates that it could take 9 - 12 months to set up an HCS, 
and a further 6 months to co-ordinate testing across multiple sites.
Do the ethics arguments take all 
scientific concerns into account?
As a point of departure, ethics debates usually require a thorough 
interrogation of the science. In considering HCSs, it is important 
to consider model endpoints – will a disease model or an infection 
model be adopted? With an infection model, the endpoint is 
verification of infection, not disease. The malaria HCS is a prototype 
of this model. In a disease model, the endpoint is a specified clinical 
illness and is usually used when infection is difficult to measure. 
Enteric challenge models are an example of such a disease model. 
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Whether a disease or an infection model is chosen depends on the 
disease under discussion, the purpose of the model, the availability 
of treatment and the reproducibility of the model.[22] For COVID-19, 
the nasally administered inoculate is intended to produce mild upper 
respiratory tract illness, and viral shedding will be assessed.[23] It is 
also important that the endpoint chosen will not place the research 
participant at risk of severe disease. In dengue fever, for example, 
most infections are asymptomatic or mildly symptomatic. With 
COVID-19, progression from mild to severe disease is unpredictable 
even in young adults.
Choosing the appropriate challenge strain is also critical, as either 
a wild-type human strain or a recombinant strain can be selected. 
What happens when variants emerge while HCSs are already 
underway? During the second wave of infection in many countries, 
including SA, new variants have emerged.[13] It is important to know 
whether the strain will be transmissible to third parties because of 
viral shedding. The latter risk could be averted by ensuring adequate 
isolation after inoculation with the challenge strain.
Some ethics conversations overlook important scientific aspects of 
challenge models for COVID-19. In particular, the test population 
may not be immunologically representative of the target population 
if young volunteers are selected to participate in an HCS of a disease 
that adversely and disproportionately affects older people. It is a big 
assumption that HCSs will speed up vaccine development, and very 
problematic that the clinical disease spectrum is so huge. We currently 
have no idea whether the immune response in mild disease helps us 
at all with understanding the problematic immune manifestations 
in severe disease. Traditional clinical trials can set eligibility criteria 
to study mild and severe disease and enrol participants with a broad 
age range from young adults to older participants. Young adults are 
more likely to develop mild disease, while older participants are likely 
to develop more severe disease. HCSs enrolling young adults may 
improve our understanding of mild COVID-19 disease, but the ethics 
of such studies are questionable when the utility of such information 
for the prevention of severe disease is unclear, and when a small 
percentage of young adults deliberately infected in such trials may 
experience severe disease or even death.[7]
Will HCSs work in SA?
Most of the ≥40 000 human volunteers in (non-COVID-19-related) 
HCSs to date have been in high-income countries. While there is 
an ethical imperative to conduct HCSs in low- and middle-income 
countries (LMICs), when COVID-19 is rampant, it is important to 
consider many factors.[24] From an ethical perspective, one of the 
biggest challenges may be ensuring an authentic consent process 
that is not compromised by the lure of remuneration in low-income 
settings. If the risk of harm to third parties is to be mitigated by a 
prolonged period of isolation (~17 days) after deliberate infection, 
for example, the remuneration for time, inconvenience and other 
expenses is likely to be substantial in the context of socioeconomic 
disadvantage. While compensation for study-related burdens may be 
defensible in SA, as this is the norm for clinical trials, compensation 
for study-related risk-taking is more controversial. Some have 
argued that it is unfair to ask HCS participants to expose themselves 
to uncompensated risks for the good of society, and that they 
should be given ‘danger pay’.[25] From their experiences of malaria 
challenge studies in Kenya, Njue et al.[26] argue that with appropriate 
information and investment in adequate community engagement to 
build trust, HCS participants can reason for themselves about how 
to balance risk and renumeration, using research renumeration to 
support what they value, such as school fees, debt, investments and 
training. However, there are ethically significant differences between 
malaria and COVID-19 HCSs, in particular the fact that there are 
effective treatments for malaria and that COVID-19 HCSs require 
special care of participants that may be scarce in fragile health 
systems during a pandemic. For this reason, proceeding with HCSs 
in contexts such as SA requires a compelling scientific justification, a 
safety-enhancing research infrastructure, and participants who grasp 
the risks they face.
Concerns around justice also exist. Two considerations are 
important here – the implementation gap and vaccine uptake. The 
implementation gap – the gap between vaccine licensure and vaccine 
access – could be prolonged in LMICs.[7] Vaccines are currently being 
rolled out in the Global North, yet SA anticipates limited vaccine 
access in the first quarter of 2021. Once access is assured, uptake 
of the vaccine is important. SA has had a history of reasonable 
childhood immunisation coverage, reaching ~82% prior to the 
pandemic.[27] However, a recent Ipsos survey commissioned by the 
World Economic Forum has demonstrated that only 64% of South 
Africans would accept a COVID-19 vaccine.[28] While the validity of 
generalising these findings is unclear, vaccine hesitancy is growing 
in prominence in Africa.[29] Given the history of research-related 
exploitation in Africa, public trust in science, research and vaccines 
is waning and adverse outcomes could result in reputational harm to 
vaccine research and vaccine uptake in general.[30,31]
The benefits of HCSs for vaccine development will only be 
realised if there is a guarantee that there will be adequate uptake 
of the vaccine once it is available. We cannot justify HCSs by their 
benefits to society, in the absence of assurance that the LMICs that 
bear the risk burden will progress to availability of the vaccine for 
the whole population and will achieve adequate coverage.[7] High-
income countries have bought up or are busy buying up vaccine 
stocks in advance.[32] This delay in vaccine access also undercuts the 
‘acceleration argument’, since what good will it do for LMICs to speed 
up vaccine development by means of HCSs, if vaccine distribution 
will not be going at ‘warp speed’ for them?
Conclusions
Although HCSs were proposed as an accelerated pathway to vaccine 
development early in the pandemic when the comparison with 
traditional clinical trial timelines was made, the speed with which 
recent traditional COVID-19 vaccine research has occurred has 
resulted in a few efficacious candidate vaccines that have emerged 
from phase 3 testing. In this context, the arguments that support HCSs 
based on urgency and speed have become less compelling. Unlike 
other diseases in which HCSs have been conducted safely, COVID-
19 is immunologically complex and unresolved, there is no definitive 
treatment to date, and severity of disease outcome, including death, 
has not been consistent across the age spectrum. Enrolling younger 
participants only limits generalisability, as younger participants may 
be immunologically distinct from the elderly who are at higher risk. 
The AstraZeneca COVID-19 vaccine trial in SA is a prime example, 
where data on younger participants could not be extrapolated to 
the elderly who carry the risk of more severe disease. [16] Deliberate 
infection of healthy participants with a potentially lethal virus does 
not augur well in a global context of distrust of science and vaccine 
hesitancy. The alternative is an accelerated conventional vaccine 
development pipeline where regulatory bodies are balancing safety 
and speed. On the assumption that the vaccines being distributed 
now are beneficial, and since they are becoming available at warp 
speed, this expedited vaccine development confers the benefits of 
HCSs with fewer risks and fewer ethics complications. For these 
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reasons, along with the challenges with consent processes for research 
on less complex diseases than COVID-19, conducting HCSs in 
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